Eight months ago, Dewpoint Therapeutics cut 70% of its workforce.
The company was founded in 2019 by two giants: Anthony Hyman, who basically invented the field of biomolecular condensates, and Richard Young, who figured out how condensates regulate gene transcription. Nobel laureate Phillip Sharp chaired the scientific advisory board. Bayer, Novo Nordisk, and Mitsubishi Tanabe all signed partnerships. Dewpoint raised approximately $287 million across Series A, B, and C.
Then 2025 happened. The workforce got slashed. The pipeline narrowed. Resources got concentrated on a single lead asset, DPTX3186, a first-in-class oral c-mod targeting beta-catenin for Wnt-driven cancers. The FDA opened its IND last year. The Phase 1 trial NCT07312903 is recruiting 40 patients with solid tumors right now.
That was the survival plan. Get DPTX3186 into patients. Generate proof-of-concept data in 2026. Live to fight another day.
So it’s interesting that at AACR this week, Dewpoint showed up with a second program.
Dewpoint pipeline
DPTX3186 — Wnt-driven solid tumors
Oral c-mod · beta-catenin condensate modulator
MYC c-mod — MYC-driven solid tumors
Oral small molecule · MYC condensate modulator
The new asset is an oral MYC condensate modulator. Preclinical data. Tumor regression and selective activity in MYC-high cells, with a tolerability profile the company described as favorable.
Here’s why that matters. MYC has been called undruggable for forty years.
It’s the single most frequently dysregulated oncogene in human cancer. An estimated 70% of tumors depend on it. And nobody can touch it directly, because MYC is an intrinsically disordered protein with no classic binding pocket. You can’t dock a small molecule against a blob.
Dewpoint’s play is to sidestep the protein entirely. MYC works by forming transcriptional condensates with its co-factors to drive oncogenic gene expression. If you disrupt the condensate instead of the protein, you can shut down MYC activity without ever needing to bind MYC itself.
Same logic they applied to beta-catenin with DPTX3186. Now they’re running it at the biggest undruggable target in oncology.
It’s the same underdog-story structure you see in molecular glue degraders and other “undruggable target” plays. Get around the protein by hijacking an adjacent biology.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
So what do you do with a company that cut 70% of its workforce and is now walking into AACR with a second program?
You watch DPTX3186. If the Phase 1 generates real signal in Wnt-driven tumors, the whole condensate-modulator thesis moves from speculative to validated. And suddenly a preclinical MYC program at the same company becomes one of the most valuable assets in oncology.
If DPTX3186 doesn’t deliver, the MYC program is an academic poster.
Proof-of-concept data is expected later this year. Book the calendar.
